EVMN EVOMMUNE INC revenue, earnings and financials
For the quarter ended June 30, 2026, EVOMMUNE INC reported revenue of $0, net income of −$32.2M and diluted EPS of −$0.89; over the last four quarters revenue was $10.0M and net income −$94.7M; for the fiscal year ended December 2025 revenue was $13.0M, up 85.7% on the year before.
EVMN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $13.0M, gross profit n/a, operating income −$81.1M, net income −$68.9M (margin -529.8%), EPS −$11.22
- Fiscal year ended Dec 2024: revenue $7.00M, gross profit n/a, operating income −$70.0M, net income −$66.8M (margin -954.4%), EPS −$45.29
EVMN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income −$32.2M, EPS −$0.89
- Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$21.7M, EPS −$0.64
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0, net income −$28.3M, EPS $15.13
- Quarter ended Sep 30, 2025: revenue $10.0M, net income −$12.5M, EPS −$8.07
- Quarter ended Jun 30, 2025: revenue $0, net income −$13.6M, EPS −$8.80
- Quarter ended Mar 31, 2025: revenue $3.00M, net income −$14.6M, EPS −$9.48
- Quarter ended Sep 30, 2024: revenue n/a, net income −$15.9M, EPS −$10.47
EVMN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$76.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$58.2M, share buybacks n/a
EVMN balance sheet
- Jun 30, 2026: cash $60.0M, total assets $302M, total liabilities $24.4M, shareholders' equity $278M
- Mar 31, 2026: cash $48.3M, total assets $322M, total liabilities $17.9M, shareholders' equity $305M
- Dec 31, 2025: cash $44.1M, total assets $225M, total liabilities $19.4M, shareholders' equity $206M
- Sep 30, 2025: cash $26.8M, total assets $84.5M, total liabilities $10.7M, shareholders' equity −$183M
- Dec 31, 2024: cash $16.3M, total assets $76.1M, total liabilities $28.5M, shareholders' equity −$144M
What is EVMN's revenue?
EVOMMUNE INC reported $10.0M of revenue over its last four quarters, through June 30, 2026.
Is EVMN profitable?
No. EVOMMUNE INC lost $94.7M over the last four quarters.
What is EVMN's EPS?
Diluted earnings per share over the last four quarters were $5.53; −$0.89 in the latest quarter.